Benchmark initiated coverage of Prenetics with a Buy rating and $30 price target. The health and wellness company is focused on IM8, its consumer brand addressing the growing nutritional supplements market that was co-founded by David Beckham, the analyst noted. The firm believes the company has a viable long-term growth strategy built on logical product expansion and adjacencies, further marketing channel diversification, and increasing global reach, the analyst tells investors.
